HeartSciences announces Baker Institute ECG LV Dysfunction Study Results Published in JACC – Cardiovascular Imaging

Demonstrates Potential for ECG screening for LV dysfunction in asymptomatic patients with ejection fraction > 40%  

 

SOUTHLAKE, Texas, June 28, 2021 – HeartSciences, a medical device company focused on advancing the field of electrocardiology through innovation, announced the results of a study by Australia’s Baker Heart and Diabetes Institute focused on identifying asymptomatic heart failure patients using machine learning based ECG testing.

Increases in healthcare expenditures remains a global widespread issue. The overuse of expensive diagnostic testing has been identified as a contributing factor. More effective low-cost front-line tools are needed that help identify at-risk patients earlier while lowering costs for health systems around the world.  Currently no viable screening test exists to improve referral for echocardiography, however recent studies have demonstrated the ability to detect LV dysfunction in patients with LVEF <= 40%.  This study evaluated the feasibility of using ECG-based machine learning to effectively screen for patients at-risk for subclinical systolic and diastolic left ventricular dysfunction (LVD) and thus potentially reduce the number being referred on to echocardiography.

The results were published in JACC- Cardiovascular Imaging.  The article by Elizabeth L. Potter, MBBS, BSc, Thomas H. Marwick, MBBS, PHD, MPH, Partho P. Sengupta, MD, et. al. is titled “Machine Learning of ECG Waveforms to Improve Selection for Testing for Asymptomatic Left Ventricular Dysfunction Prompt.”  The machine learning ECG algorithm using MyoVista wavECG technology was developed by Potter et.al. to determine if it could effectively screen for LV dysfunction in asymptomatic patients with EF > 40%.

A supervised machine-learning approach was used to develop an algorithm using HeartSciences MyoVista® wavECG™ CWT frequency-based features. The ARIC HF score was also included to evaluate the importance of this easily attainable clinical variable against wavECG frequency related variables.

 

The study included 398 participants (57% female, median age 69 years), and of these, 171 (43%) had LVD. The developed algorithm using CWT features alone was tested in an independent group (n =111; 49% female, median age 61 years), and demonstrated 88% sensitivity and 70% specificity (area under the receiver-operating curve or AUC) of 0.78. The ARIC HF risk score had an AUC of 0.72 for LVD discrimination. An optimized cutoff point for sensitivity was identified as an ARIC HF risk score of 2.6, providing 90% sensitivity and 40% specificity. The AUC for NT-proBNP was 0.53, with an optimized cutoff of 21 pg/ml providing a sensitivity of 88% and specificity of 14%. An abnormal ECG, as determined by conventional ECG software-based analysis, provided a sensitivity of 36% and a specificity of 85%. In those with available NT-proBNP, adding NT-proBNP to the ARIC HF risk score (AUC 0.65) did not significantly improve discriminatory ability versus ARIC alone (AUC 0.63). Furthermore, the addition of both NT-proBNP and abnormal conventional ECG results did not significantly improve discriminatory ability (AUC 0.67)

Results of the study: “Conventional candidates for LVD screening (ARIC score, N-terminal pro–B-type natriuretic peptide, and standard automated ECG analysis) had inferior discriminative ability. Integration of ewECG [HeartSciences wavECG] in screening of people at risk of HF would reduce need for echocardiography by 45% while missing 12% of LVD cases. “

“This new study by Baker Institute using MyoVista’s wavECG Technology further demonstrates the ability of MyoVista wavECG Technology to detect LV dysfunction.” stated Mark Hilz, President and CEO of HeartSciences.

Andrew Simpson, Chairman of HeartSciences, stated “This study further indicates that HeartSciences MyoVista wavECG’s innovative technology has the potential to significantly improve low-cost front-line testing for heart disease”.

About HeartSciences

HeartSciences sits at the forefront of innovation and technological development focused on advancing the field of electrocardiology to provide early heart disease detection.  Its first product, the MyoVista® Wavelet ECG (wavECG™) Cardiac Testing Device, is a resting 12-lead electrocardiograph that uses AI and continuous wavelet transform (CWT) signal processing to provide cardiac information associated with left ventricular diastolic dysfunction (LVDD), a condition which has previously not been possible to detect using conventional electrocardiology. LVDD is associated with almost all forms and co-morbidities of heart disease and may include hypertension, diabetes, valvular disease, ischemia, and reduced systolic function, among others.

The MyoVista Device additionally provides all the information and capabilities of a full-featured conventional resting 12-lead ECG within the same test and follows the same clinical AHA/IEC lead placement protocol.

HeartSciences is a privately held U.S. corporation based in Southlake, Texas.

The MyoVista Device is not currently FDA cleared and is not available in the United States.

For more information visit www.heartsciences.com.

 

Contact

HeartSciences
Gene Gephart
gene.gephart@heartsciences.com

HeartSciences Announces Pilot Study Results published in launch edition of European Heart Journal-Digital Health

Study demonstrates MyoVista® wavECG™ ability to predict abnormal Calcium Score

Heart disease is a global pandemic affecting at least 26 million people worldwide and continues to increase in prevalence due to increasing life expectancy in the general population. More effective front-line tools are needed that can assist in identifying patients earlier while also lowering costs for health systems around the world. The article is titled “Prediction of coronary artery calcium scoring from surface electrocardiogram in atherosclerotic cardiovascular disease: a pilot study”.  The study evaluated the feasibility of MyoVista Technology to assist in predicting abnormal calcium scores.

Conclusion of the study: “ML techniques can extract information from electrocardiographic data and clinical variables to predict CAC score categories and similarly risk-stratify patients with suspected coronary artery disease.”

See the full Press release:  https://heartsciences.com/wp-content/uploads/2020/12/ESC-Digital-Health-press-release-Dec-2020.pdf

HeartSciences Announces Clinical Study Results in the Journal of the American College of Cardiology (JACC)

Study demonstrates MyoVista® wavECG™ ability to cost-effectively detect LV Dysfunction

 

SOUTHLAKE, Texas, August 18, 2020 – HeartSciences, a medical device company focused on advancing the field of electrocardiology through innovation, announced today the results of a multicenter prospective study conducted at 4 centers in North America enrolling a total of 1,202 subjects. The study was supported in part by funds from HeartSciences and the National Science Foundation. The results are provided at online JACC.org and will be published in the August 25, 2020 issue of Journal of the American College of Cardiology (JACC), a peer-reviewed journal in cardiovascular medicine. The participating centers are The Icahn School of Medicine, Mount Sinai Hospital, New York, NY, The West Virginia University (WVU) Heart and Vascular Institute, Morgantown, WV, The Windsor Cardiac Centre, Windsor, Ontario, Canada and the David Geffen School of Medicine at UCLA, Los Angeles, California.

The article titled “Machine Learning Assessment of Left Ventricular Diastolic Function Based on Electrocardiographic Features” presents the results from evaluating the feasibility of MyoVista® wavECGTM  Technology to provide quantitative estimates related to myocardial relaxation that can be used to identify left ventricular diastolic dysfunction (LVDD). Diastolic dysfunction is recognized as playing a major role in the pathophysiology of heart failure.  Heart disease is a global pandemic affecting at least 26 million people worldwide and continues to increase in prevalence due to increasing life expectancy in the general population.  New tools are needed that can assist in identifying patients earlier while also lowering costs for health systems around the world.

The study was performed using machine learning analysis often described as artificial intelligence or AI. Machine-learning models were developed to estimate e’ (e-prime) using signal-processed ECG features, traditional ECG features and clinical information. Patients from 3 institutions (n= 814) formed a development cohort and were randomly divided into training and internal test sets (80:20).  Data from the fourth institution was reserved as an external test set (n = 388) to evaluate model performance.

The study results demonstrated that the estimated e’ values discriminated the guideline-recommended thresholds for abnormal myocardial relaxation, LVDD and systolic dysfunction (LV ejection fraction) with an AUC of 0.84, 0.80, and 0.81 respectively in the external test set.  Moreover, the estimated e’ allowed prediction of LV diastolic dysfunction based on multiple age and sex-adjusted reference limits with an AUC of 0.94 in the external test set.

Conclusions of the study include: “This cost-effective strategy may be a valuable first clinical step for assessing the presence of LV dysfunction and potentially aid in the early diagnosis and management of heart failure patients” and “This novel approach has the potential to serve as a cost-effective screening tool for early detection of LVDD.”

Partho Sengupta, MD, Professor, Chief of Cardiology and Chair of Cardiac Innovation, WVU Heart & Vascular Institute, the principal investigator commented “The study focused on developing a quantitative estimation of a key echocardiographic measure. The results demonstrate a potentially significant new role for electrocardiography in cardiac testing and reducing overall healthcare costs”

“This large-scale study using MyoVista wavECG Technology, demonstrates that new LV dysfunction detection capabilities developed using advanced signal processing and AI can provide improved low-cost testing for heart disease.” stated Mark Hilz, President and CEO of HeartSciences.

Andrew Simpson, Chairman of HeartSciences, stated “This study indicates that HeartSciences MyoVista wavECGs innovative technology has the capability and opportunity to bridge the diagnostic gap in heart disease”.

About HeartSciences

HeartSciences sits at the forefront of innovation and technological development focused on advancing the field of electrocardiology to provide early heart disease detection.  Its first product, the MyoVista® Wavelet ECG (wavECG™) Cardiac Testing Device, is a resting 12-lead electrocardiograph that uses AI and continuous wavelet transform (CWT) signal processing to provide cardiac information associated with left ventricular diastolic disfunction (LVDD), a condition which has previously not been possible to detect using conventional electrocardiology. LVDD is associated with almost all forms and co-morbidities of heart disease and may include hypertension, diabetes, valvular disease, ischemia, and reduced systolic function among others.

The MyoVista Device additionally provides all the information and capabilities of a full-featured conventional resting 12-lead ECG within the same test and follows the same clinical AHA/IEC lead placement protocol.

HeartSciences is a privately held U.S. corporation based in Southlake, Texas.

The MyoVista Device is not currently FDA cleared and is not available in the United States.

For more information visit www.heartsciences.com.

Contacts

HeartSciences
Gene Gephart
gene.gephart@heartsciences.com

MyoVista Wavelet ECG Cardiac Testing Device Showcased at 2019 ESC – Paris, France

MyoVista Wavelet ECG Cardiac Testing Device Showcased at 2019 ESC – Paris, France

HeartSciences, a medical device company developing next generation ECG devices using continuous wavelet transform (CWT) signal processing and artificial intelligence, is proud to have participated as an exhibitor at the 2019 European Society of Cardiology Congress (ESC) in Paris, France from August 31 to September 4, 2019. HeartSciences is advancing the field of electrocardiography through the application of wavelet signal processing and artificial intelligence to develop next generation ECG technology.

MedTech Strategist Names HeartSciences as Start-Up to Watch

HEARTSCIENCES:
Artificial Intelligence Improves Frontline Risk Stratification for Heart Diseases

The current screening paradigm for heart disease is missing people at early stages, when diseases are most treatable. HeartSciences has taken a ubiquitous screening tool, the 12-lead ECG, and has, through the application of signal processing and artificial intelligence, turned it into a powerful tool that can detect diastolic dysfunction, an early indicator of most cardiac diseases.

HeartSciences: AI Improves Frontline Risk Sratification for Heart Diseases

 

HeartSciences Announces Professor Peter Macfarlane Joins Clinical Advisory Board

Professor Peter W. Macfarlane, DSc eFESC FRSE, is an expert in the field of electrocardiology and has over 40 years’ experience in the development of computer-based systems for the interpretation of ECGs. He has authored over 300 publications and peer-reviewed papers, as well as numerous books on the subject. Professor Macfarlane is recognized as a pioneer in the use of computers in hospital-based ECG interpretation. The work of his team has been adopted commercially, and the University of Glasgow ECG interpretation analysis developed in his laboratory is currently used worldwide. The Glasgow analysis is incorporated in the MyoVista® wavECG™ Device where it complements HeartSciences by providing computerized analysis of the conventional ECG waveform. At present, he is Emeritus Professor and Honorary Senior Research Fellow of the University of Glasgow. In 2014, Professor Macfarlane was awarded a CBE for services to British healthcare.

 

Peter is the current President of the International Society of Computerized Electrocardiology (ISCE). He also serves as Treasurer of the International Society of Electrocardiology (ISE), having been President in the past. His major interest throughout his career has been the application of computer techniques to ECG interpretation.

 

“HeartSciences’ use of computerized techniques, such as signal processing and artificial intelligence, is truly innovative.  I look forward to contributing to HeartScience’s success,” said Macfarlane.

 

“HeartSciences is honored to have Peter join our Clinical Advisory Board. His wealth of experience and expertise in the application of computer techniques in electrocardiology aligns well with the company’s technology and vision for the future,” said Mark Hilz, chief executive officer of HeartSciences. “We look forward to working with Peter to achieve our shared goals of improving ECG capabilities for the detection of heart disease.”

 

About HeartSciences

HeartSciences is leading innovation in the field of electrocardiology through the application of continuous wavelet transform (CWT) signal processing and artificial intelligence. Wavelet signal processing is currently used in many different industries as an important tool to provide insights and new valuable data related to spectral analysis of a signal. HeartSciences’ MyoVista® Wavelet ECG (wavECG™) Device is a first-to-market 12-lead resting electrocardiograph with new informatics based on wavelet signal processing. Patented informatics focus on energy-related information rather than conventional voltage-based information. HeartSciences’ mission is to enable accurate, affordable screening for the early detection of heart disease.

In addition to proprietary informatics, the MyoVista wavECG Device has full 12-lead resting ECG capabilities including analysis using the Glasgow Algorithm, one of the world’s most respected interpretive algorithms. The device has a 15.6-inch high-resolution touchscreen display and incorporates many features commonly associated with a tablet device, requiring minimal user training with no change in ECG clinical workflow. The MyoVista wavECG Device is not currently available for commercial sale or distribution in the United States.

HeartSciences is a privately-held U.S. corporation based in Southlake, Texas.

For more information visit www.heartsciences.com.

HeartSciences Announces Publication of Clinical Study Results in the Journal of the American College of Cardiology (JACC)

HeartSciences Announces Publication of Clinical Study Results in the Journal of the American College of Cardiology (JACC)

Study demonstrates promising new capabilities for MyoVista® ECG device in detecting Abnormal Cardiac Function

HeartSciences Announces Publication of Clinical Study Results in the Journal of the American College of Cardiology (JACC)

HeartSciences Announces Poster Presentation at the 2018 American College of Cardiology Scientific Sessions

Poster Title: Prediction of Cardiac Mechanical Relaxation Abnormalities from Surface ECG Wavelets

Date: Sunday, March 11, 2018 at 3:45 p.m.

Location: Orange County Convention Center | 9800 International Drive | Orlando, Florida 32819 USA | Hall A/B

Poster: 1238-107

HeartSciences will participate in the Future Hub at ACC 2018. Future Hub is a multi-vendor educational venue to inform, educate and inspire ACC 2018 attendees by exposing them to the latest innovations in Digital Health, Medical Devices, and Ed Tech (Educational Technology). HeartSciences will be located at space FH7 of the Future Hub to present the MyoVista® spECG™ technology.

About HeartSciences

HeartSciences is advancing the field of electrocardiography through the latest research in heart disease in combination with the application of the latest technology. HeartSciences applies wavelet signal processing and artificial intelligence to develop breakthrough ECG technology. Wavelet signal processing is used in many different industries as a valuable tool that provides insights and new valuable data related to spectral analysis of a signal.

HeartSciences, a Fierce Innovation Award Finalist, will present at Biotech Showcase Events in San Francisco on January 9 and 10, 2018

HeartSciences Logo

 

SOUTHLAKE, TEXAS – January 3, 2018 – HeartSciences, a medical device company recently selected as a finalist for the Fierce Innovation Awards in the Digital Health Solution category, will be presenting in San Francisco at the BioTech Showcase.  HeartSciences has two scheduled presentations: (1) Tuesday, January 9 at the BioTech Showcase at 2:45pm at the Hilton Hotel, Union Square and (2) Wednesday, January 10 at the Digital Medicine and Technology Showcase at 10.00am, at the Parc 55 Hotel.

 

HeartSciences is advancing the field of electrocardiology in combining the latest research and understanding of heart disease with the patented use of wavelet mathematics and artificial intelligence to develop medical devices for the early detection of heart disease.  Its MyoVista hsECG (high sensitivity ECG), is designed to significantly improve the sensitivity of a diagnostic electrocardiology device in detecting ischemic and structural heart disease at an early stage.  Through the patented use of Continuous Wavelet Transform digital signal processing it measures the heart’s energy during its cardiac cycle. Recent clinical trials demonstrate MyoVista’s ability to detect cardiac dysfunction in the diastolic phase, which is known as Diastolic Dysfunction. The MyoVista hsECG, includes all the conventional information of a full featured 12-lead resting ECG plus new energy related informatics assisting in the early detection of heart disease.

 

HeartSciences was selected as a Fierce Innovation Award Finalist in December 2017 for its innovative, MyoVista® hsECG™ (high sensitivity ECG) device. Finalists were selected from a highly competitive list of innovators by a distinguished panel of judges. All applications were evaluated based on the following criteria: Competitive Advantage, Financial Impact/Value, Market Need, and Overall Innovation. Applicants with the top 3 scores in each category were selected as finalists.  Life Sciences Edition 2017, is an awards program from the well-known e-publisher of FierceBiotech and FiercePharma.

 

About HeartSciences

HeartSciences is advancing the field of electrocardiology in combining the latest research and understanding of heart disease with the patented use of wavelet mathematics and artificial intelligence to develop medical devices for the early detection of heart disease.  HeartSciences is bridging today’s “diagnostic gap” in cardiac care by developing new low-cost effective solutions that assist in identifying at-risk patients.

 

HeartSciences’ MyoVista® hsECG™ Cardiac Testing Device is a new 12-lead resting electrocardiograph utilizing continuous wavelet transform (CWT) based signal processing. It’s patented signal processing method measures myocardial energy during the cardiac cycle. Proprietary informatics focus on abnormalities related to cardiac energy levels in addition to providing traditional ECG information.

 

In addition to the proprietary informatics, MyoVista hsECG also features the capabilities of a full featured 12-lead resting ECG including analysis using the Glasgow Algorithm, one of the world’s most respected interpretive algorithms.

 

HeartSciences (formerly known as Heart Test Laboratories) is a privately-held U.S. corporation based in Southlake, Texas.

 

For more information visit www.heartsciences.com.

 

Corporate contact

Gene Gephart

+1 737 346 1089

gene.gephart@heartsciences.com